Fusion Antibodies plc
FAB.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.06 | 0.04 | 0.01 |
| FCF Yield | -3.21% | -10.49% | -32.23% | -21.43% |
| EV / EBITDA | -41.91 | -6.29 | -2.62 | -1.05 |
| Quality | ||||
| ROIC | -74.25% | -137.16% | -67.01% | -46.54% |
| Gross Margin | 22.08% | 13.85% | 26.93% | -9.41% |
| Cash Conversion Ratio | 1.12 | 0.64 | 0.99 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.04% | -27.27% | -22.71% | -12.75% |
| Free Cash Flow Growth | -2.09% | 17.29% | -78.62% | 68.86% |
| Safety | ||||
| Net Debt / EBITDA | -0.29 | 0.38 | 0.55 | 1.50 |
| Interest Coverage | -91.00 | 0.00 | -397.00 | -436.50 |
| Efficiency | ||||
| Inventory Turnover | 2.40 | 2.43 | 3.83 | 1.42 |
| Cash Conversion Cycle | 38.78 | 25.22 | 37.74 | 108.72 |